Nussbaum Law Group, P.C. and Roberts Law Firm US, PC Announce a $73.5 Million Class Action Settlement with Mylan on Behalf of Direct Purchasers of EpiPen® or Generic EpiPen
By AP News - Mar 13, 2025, 10:03 AM ET
Last Updated - Mar 13, 2025, 10:03 AM EDT
NEW YORK--(BUSINESS WIRE)--Mar 13, 2025--
Nussbaum Law Group, P.C. and Roberts Law Firm US, PC:
COURT-ORDERED LEGAL NOTICE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF KANSAS |
If you purchased EpiPen® or generic EpiPen directly from the manufacturer, you may receive a payment from a $73.5 million class action settlement. KPH Healthcare Services, Inc. v. Mylan N.V., Case No. 2:20-cv-02065-DDC-TJJ (District of Kansas) This is not a recall, safety, or other similar notice. No one is claiming that EpiPen is unsafe or ineffective. For more information and to file a claim, visit www.EpiPenDPPSettlement.com. |
WHAT DOES THE SETTLEMENT PROVIDE? A proposed settlement (“Settlement”) has been reached in a class action lawsuit alleging that Mylan N.V., Mylan Pharmaceuticals, Inc., and Mylan Specialty L.P. (together, “Mylan”) entered into an improper market allocation agreement with Pfizer, Inc., King Pharmaceuticals, Inc. (n/k/a King Pharmaceuticals LLC) and Meridian Medical Technologies, Inc. (collectively, “Pfizer”), and Teva Pharmaceuticals USA, Inc. (“Teva”) that delayed the launch of generic EpiPen and extended Mylan’s and Pfizer’s alleged monopoly over the epinephrine autoinjector market. Under the settlement, Mylan agreed to pay $73,500,000 into a settlement fund (“Settlement Fund”) for the Direct Purchaser Settlement Class. Mylan strongly denies that it violated any laws and contends that its actions enhanced competition and did not cause Class Members any injury. The Class claims against Pfizer were resolved by an earlier settlement. The Court granted final approval of that settlement on July 9, 2024. The separate Settlement that is the subject of this Notice is only with Mylan and resolves only the claims against Mylan. |
WHO IS INCLUDED? People or entities who purchased EpiPen® or generic EpiPen directly from Mylan or Teva, for resale, at any time during the period from March 13, 2014, until the date on which the Court entered the Preliminary Approval Order, February 6, 2025. Excluded from the Class are Defendants and their officers, directors, management, employees, predecessors, subsidiaries, and affiliates, and all federal governmental entities. |
HOW CAN YOU GET A PAYMENT? If you submitted a claim in the Pfizer Settlement in this case, you do not have to submit another claim to receive a payment in this Settlement. However, you have the opportunity to submit supplemental information if you wish to do so. If you did not submit a claim and you are a member of the Class, you must submit a Claim Form online at www.EpiPenDPPSettlement.com or by mail to get paid in this settlement. You may have received a Claim Form. If not, a Claim Form is available at www.EpiPenDPPSettlement.com. See the Claim Form for instructions on how to submit a claim. If the Court approves the Settlement, claims will be paid after any appeals are resolved. The deadline to postmark or submit your claim online at www.EpiPenDPPSettlement.com or by email to info@EpiPenDPPSettlement.com is May 29, 2025. |
YOUR OTHER LEGAL RIGHTS AND OPTIONS
OBJECT | | You may write to the Court about why you object to the Settlement, the request for attorneys’ fees, reimbursement of expenses and costs, and/or the plan of allocation. If you object to the Settlement, you are still a member of the Class and you must file a claim to receive a payment. Objections must be filed with the Court and received by the parties on or before April 11, 2025. |
OPT OUT | | You may write to the Settlement Administrator and exclude yourself from the Class. Exclusion allows you to file your own lawsuit. If you exclude yourself, you will not receive any payment and will not be bound by the releases contained in the Settlement. The exclusion deadline is April 11, 2025. |
DO NOTHING | | If you already submitted a claim in the Pfizer Settlement in this lawsuit and do not wish to submit supplemental information, you do not need to do anything to receive a payment from the Mylan Settlement. If you HAVE NOT previously submitted a claim, you will not receive any payment. You will, however, still be bound by the releases contained in the Settlement and will not be able to file or continue to pursue your own lawsuit. |
| |
The Court scheduled a final approval hearing for May 9, 2025, at 1:30 p.m. Central Time to consider whether the settlement and plan of allocation are fair, reasonable, and adequate, as well as any objections to the settlement, the plan of allocation, and any request for attorneys’ fees, and reimbursement of expenses and costs. You do not need to attend, but you or your attorney can do so at your own expense. |
For more information about the Settlement and your options, please visit www.EpiPenDPPSettlement.com or call 1-866-778-6568. |
View source version on businesswire.com:https://www.businesswire.com/news/home/20250310572911/en/
CONTACT: Linda P. Nussbaum
(917) 438-9189
lnussbaum@nussbaumpc.comMichael L. Roberts
(501) 821-5575
admin@robertslawfirm.us
KEYWORD: UNITED STATES NORTH AMERICA NEW YORK KANSAS
INDUSTRY KEYWORD: CLASS ACTION LAWSUIT PROFESSIONAL SERVICES LEGAL
Sponsored
SOURCE: Nussbaum Law Group, P.C. and Roberts Law Firm US, PC
Copyright Business Wire 2025.
PUB: 03/13/2025 10:00 AM/DISC: 03/13/2025 10:03 AM
http://www.businesswire.com/news/home/20250310572911/en
Sponsored
